Protagonist Therapeutics Inc
PTGX
NASDAQ
Biotechnology
$155.10
USD
+3.68 (+2.43%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $9.93B
Volume 426.3K
Revenue
$281.99M
TTM
+34.8%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-79.94M
TTM
-192.1%
YoY
Operating Cash Flow
$-87.86M
TTM
-228.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 5.5 | 4.7 | 7.4 | 56.4 | 213.5 |
YoY Growth | +33.1% | +0.8% | -95.6% | +99.0% | +3749.2% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 5.5 | 4.7 | 7.4 | 56.4 | 213.5 |
Selling, General & Administrative | 10.6 | 11.1 | 11.4 | 13.3 | 12.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 47.6 | 51.1 | 57.8 | 60.0 | 54.7 |
Operating Income | -42.0 | -46.4 | -50.4 | -3.6 | 158.8 |
EBITDA | -42.0 | -46.1 | -50.0 | -3.2 | 158.8 |
Other Income / Expense | 0.0 | 0.0 | -0.1 | 0.1 | -0.1 |
Total Other Income / Expense | 7.4 | 7.1 | 6.6 | 5.9 | 6.3 |
Income Before Income Taxes | -34.6 | -39.3 | -43.7 | 2.3 | 165.1 |
Income Taxes | 0.2 | 0.0 | 0.7 | -1.5 | 2.3 |
Net Income | 0.0 | -39.3 | -44.4 | 3.8 | 0.0 |
Consolidated Net Income / Loss | -34.8 | -39.3 | -44.4 | 3.8 | 162.8 |
Net Income Attributable to Common Shareholders | -34.8 | -39.3 | -44.4 | 3.8 | 162.8 |
Basic EPS | -$0.55 | -$0.62 | -$0.69 | $0.06 | $2.47 |
Diluted EPS | -$0.55 | -$0.62 | -$0.69 | $0.05 | $2.29 |
Basic Shares Outstanding | 63.5M | 63.8M | 64.0M | 65.1M | 65.9M |
Diluted Shares Outstanding | 63.5M | 63.8M | 64.0M | 70.5M | 71.0M |